Printer Friendly

ATRIX LABORATORIES ANNOUNCES SECOND QUARTER AND SIX MONTH RESULTS

 FORT COLLINS, Colo., April 30 /PRNewswire/ -- Atrix Laboratories Inc. (NASDAQ: ATRX) reported a loss of $872 thousand or (11 cents) per share on revenues of $742 thousand for the second quarter ended March 31, 1993. These results compare with a loss of $4.9 million or (70 cents) per share for the second quarter ended March 31, 1992, which loss was related primarily to the purchase of all rights for the proprietary drug delivery technology from Southern Research Institute. For the six months ended March 31, 1993, the company reported a loss of $1.5 million on revenues of $1.7 million, or (20 cents) per share. This compares with a loss of $6 million or (85 cents) per share on revenues of $1.4 million for the like six month period one year ago.
 Commenting on the results, Dr. G. Lee Southard, president and chief executive officer stated, "Atrix continues to maintain a strong balance sheet with $29.5 million in cash. Our clinical trials for the Perio Products containing sanguinarine and doxycycline are proceeding as planned as is the trial for the ATRISORB(TM) Guided Tissue Regeneration Membrane." Southard also said that the results from these trials are anticipated to be available during the summer.
 Atrix Laboratories is a drug delivery company with a unique, proprietary drug delivery system that is biodegradable and can be utilized for a broad range of applications, including medical devices and the treatment of periodontal disease.
 ATRIX LABORATORIES INC.
 Statements of Operations
 For the Three Months Ended March 31, 1993 and 1992
 (Unaudited)
 1993 1992
 Revenue:
 Contract revenue - other projects $236,779 $154,538
 Contract revenue from related party -
 other projects 124,225 414,046
 Loss on sale of marketable securities (12,642) ---
 Interest income 393,910 490,217
 Total revenue 742,272 1,058,801
 Expenses:
 Research expenses-Perio Product 590,432 606,959
 Research and development expenses 760,872 500,049
 Acquisition of technology --- 4,503,000
 Administrative expenses 263,459 397,465
 Total expenses 1,614,763 6,007,473
 Net loss $(872,491) $(4,948,672)
 Loss per common share $(.11) $(.70)
 Weighted average shares outstanding 7,672,427 7,044,030
 For the Six Months Ended March 31, 1993 and 1992
 (Unaudited)
 1993 1992
 Revenue:
 Contract revenue - other projects $478,059 $196,246
 Contract revenue from related party -
 other projects 279,877 416,670
 Gain on sale of marketable securities 129,470 ---
 Interest income 785,816 749,127
 Total revenue 1,673,222 1,362,043
 Expenses:
 Research expenses-Perio Product 1,195,840 1,342,592
 Research and development expenses 1,408,724 853,019
 Acquisition of technology --- 4,503,000
 Administrative expenses 578,547 639,751
 Total expenses 3,183,111 7,338,362
 Net loss $(1,509,889) $(5,976,319)
 Loss per common share $(.20) $(.85)
 Weighted average shares outstanding 7,672,427 7,044,030
 -0- 4/30/93
 /CONTACT: Susan Sherman of Atrix Laboratories, 303-482-5868/
 (ATRX)


CO: Atrix Laboratories Inc. ST: Colorado IN: MTC SU: ERN

BB-JK -- DV003 -- 3271 04/30/93 14:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1993
Words:511
Previous Article:KYSOR INCREASES DIVIDEND 10 PERCENT
Next Article:ROYCE LABORATORIES, INC. ANNOUNCES GORDON BALTZER AS VICE PRESIDENT OF FINANCE AND BUSINESS DEVELOPMENT
Topics:


Related Articles
ATRIX LABORATORIES, INC. ANNOUNCES FIRST QUARTER RESULTS
ATRIX LABORATORIES, INC. ANNOUNCES 1995 YEAR END RESULTS
ATRIX LABORATORIES ANNOUNCES FIRST U.S. SHIPMENTS OF ATRISORB(R) GTR BARRIER AND 2ND QUARTER RESULTS
Atrix Laboratories Announces 3rd Quarter Results
Atrix Laboratories Reports 1997 First Quarter Results
Atrix to Continue Development of Cancer Therapy
Atrix To Continue Development of Cancer Therapy
Atrix Laboratories Reports 1998 First Quarter Financial Results
Atrix Laboratories Reports 2003 Second Quarter Financial Results; Highlights:.
Atrix Receives Payment for First Sale of Three Month Eligard(TM).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters